| Literature DB >> 28913682 |
Robert Berent1, Theresa Berent2, Helmut Sinzinger2.
Abstract
Treatment of lipid disorders (dyslipidemia) is the cornerstone of atherosclerosis prevention and reduction of progression. Lifestyle modification is the first step to improve the plasma lipid profile. Statins play a central role in the reduction of LDL cholesterol. Whether and to what extent other lipids such as triglycerides or lipoprotein(a) should also be treated depends on the extent of atherosclerotic disease and its progression over time. Especially in residential cardiac rehabilitation we have the opportunity to encourage adherence and adapt medication as necessary due to a face to face contact over 4 weeks. Moreover, the prescription for a PCSK9-inhibitor could be resolved or the indication for a lipoprotein apheresis could be considered.Entities:
Keywords: Hypercholesterolemia; Hypertriglyceridemia; Lipoprotein(a); PCSK9; Statins
Mesh:
Substances:
Year: 2017 PMID: 28913682 DOI: 10.1007/s10354-017-0594-y
Source DB: PubMed Journal: Wien Med Wochenschr ISSN: 0043-5341